Table 1.

Anti-osteoporotic drug targets that have been linked to changes in BMD by GWAS.

Drug Class	Drug Target	Target locus IDed through GWAS	Refs
Denosumab	RANKL	RANKL	112
Sclerostin inhibitors	Sclerostin (SOST)	SOST	113
Selective oestrogen receptor modulators	Oestrogen receptor	ESR1	114
Parathyroid hormone analogues	Parathyroid hormone (PTH) receptor	Not identified, but pathway highlighted by PTH-like hormone and PTH-related protein	115,8
Bisphosphonates	Farnesyl pyrophosphate	Not identified	116
Oestrogen	Oestrogen receptor	ESR1	117
Cathepsin K inhibitors	Cathepsin K	Not identified	118
Dickkopf 1 (DKK1) inhibitors	DKK1	DKK1	119

Table adapted from¹³.